Blood test improves lung cancer screening accuracy
News-Medical.Net — June 11, 2024, 11:00 AM UTC
Summary: A blood-based cfDNA fragmentome assay for lung cancer detection showed 84% sensitivity, 58% specificity, and 99.8% NPV. With a 0.7% lung cancer prevalence, the NNS was 143. The assay could reduce lung cancer deaths by 14,264 in high adoption scenarios. It offers a cost-effective, accurate screening tool, potentially decreasing late-stage diagnoses and fatalities.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.